Nursing for women's health
-
This year marks the 25th year of publication for Nursing for Women's Health.
-
In 2019, the U. S. Food and Drug Administration approved cefiderocol, a new treatment option for individuals with complicated urinary tract infections. ⋯ The recommended dose of cefiderocol is 2 g intravenously every 8 hours infused over 3 hours. The dose is adjusted for individuals with creatinine clearance of less than 60 ml/min or greater than 120 ml/min. Gastrointestinal symptoms such as diarrhea and constipation are the most common adverse events reported by individuals taking cefiderocol.
-
The coronavirus pandemic caused a rapid and seismic shift in the provision of nursing education. In this commentary, I provide examples of how faculty and students at my university made the shift and what we have learned from the experience thus far.
-
Nurses are at the forefront of the COVID-19 pandemic.
-
Postpartum depression is a mood disorder that affects up to 20% of women in the first year after childbirth. Symptoms can range from mild depression and anxiety to severe mood alterations and psychosis. A mainstay of treatment has included selective serotonin reuptake inhibitors. ⋯ Food and Drug Administration approved brexanolone, the first medication specifically indicated for the treatment of postpartum depression. Given as an intravenous infusion over the course of 60 hr, brexanolone has the potential to fill an unmet need for women with postpartum depression. In this column, I will provide an overview of brexanolone and discuss administration, adverse effects, and practice implications for nurses who work with childbearing women.